SCHEMBL17455993

SCHEMBL17455993

Cc1cc(CN2CCC(Oc3cccnc3-c3ccncc3)CC2)no1

nearest known ligand 0.37

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ IKBKE Q14164 1/20 0.37
▸ TBK1 Q9UHD2 1/20 0.37
▸ TLR9 Q9NR96 3/20 0.37
▸ TLR8 Q9NR97 3/20 0.37
▸ TLR7 Q9NYK1 3/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ PRKAA2 P54646 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ RIPK3 Q9Y572 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GRIN1 Q05586 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ NMT1 P30419 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455986 0.85 KMT2A (0.39) NPC1CYP11B1CYP11B2SMN1; SMN2
SCHEMBL17455954 0.83 ALDH1A1 (0.48) NPC1CYP11B1CYP11B2LMNASMN1; SMN2
SCHEMBL17455921 0.82 CYP11B1 (0.42) CYP11B1CYP11B2SMN1; SMN2
SCHEMBL17456009 0.81 SCN9A (0.47) CYP11B1CYP11B2LMNASMN1; SMN2
SCHEMBL17455973 0.81 SCN9A (0.46) —
SCHEMBL17455958 0.80 LTA4H (0.36) CYP11B1CYP11B2SMN1; SMN2
SCHEMBL17455968 0.80 SMN1; SMN2 (0.53) CYP11B1CYP11B2LMNAGAASMN1; SMN2
SCHEMBL17456050 0.78 SCN9A (0.49) CYP11B1CYP11B2LMNASMN1; SMN2
SCHEMBL17456021 0.78 SCN9A (0.43) TLR9TLR8TLR7CYP11B1CYP11B2
SCHEMBL17455988 0.78 KDM4E (0.46) CYP11B1CYP11B2GAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 IKBKE 1556/4885TBK1 4469/4885TLR9 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback